PCR Spawns A New 'Copycat' Industry For Science

The battle over the extent of Cetus Corp.’s right to claim royalties on products resulting from the use of the company’s patented DNA amplification technology hasn’t kept other entrepreneurial companies from pursuing their piece of the PCR profit pie. Indeed, the explosive demand for this technology—some analysts estimate that by the year 2000 the market for DNA amplification tools will be as high as $1.5 billion—has spawned science s newest copycat industry. Muc

| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The battle over the extent of Cetus Corp.’s right to claim royalties on products resulting from the use of the company’s patented DNA amplification technology hasn’t kept other entrepreneurial companies from pursuing their piece of the PCR profit pie. Indeed, the explosive demand for this technology—some analysts estimate that by the year 2000 the market for DNA amplification tools will be as high as $1.5 billion—has spawned science s newest copycat industry.

Much of the knowledge to undertake DNA amplification is in the public domain. The primary instrument needed is a heating block, a device common to labs. The other key ingredient is the Taq polymerase enzyme, which comes from bacteria originally found in hot springs. To perform DNA amplification, a target strand of DNA is placed in a tube in the heating block, enzyme and primers are added, and, through a series of automated heating and cooling cycles, the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies